• In the past few days, commentary on Revvity (formerly PerkinElmer) has highlighted weak organic revenue growth and falling adjusted operating profits, pointing to a business under strain.
• An additional concern is that earnings per share have slipped each year over the last five years, suggesting profitability has been consistently deteriorating even though the company remains in the black.
• We’ll now explore how Revvity’s ongoing organic growth challenges could reshape its pre-existing investment narrative built around software, diagnostics and margin expansion.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Revvity Investment Narrative Recap

To own Revvity today, you need to believe that its shift toward software, diagnostics and higher-margin workflows can offset weak organic growth and declining EPS. The latest update on soft organic revenue and falling adjusted operating profits directly challenges that thesis in the near term, making execution on margin expansion the key short term catalyst and deepening the main risk that profitability erosion becomes structural rather than temporary.

Against this backdrop, Revvity’s Q1 2026 results are especially relevant. Revenue rose to US$711.12 million from US$664.76 million a year earlier, but net income dipped and EPS stayed subdued, reinforcing concerns that growth is increasingly being bought through volume and capital returns rather than underlying profitability. With only 2 to 3 percent organic growth guided for 2026, investors may question how quickly newer software and diagnostics offerings can change the story.

Yet beneath these headline numbers, there is an underappreciated risk that investors should be aware of, particularly around the company’s continued reliance on cost cuts and buybacks...

Revvity's narrative projects $3.2 billion revenue and $411.5 million earnings by 2029.

Uncover how Revvity's forecasts yield a $113.64 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts once projected Revvity’s earnings could reach about US$685 million by 2029, but recent organic growth disappointments suggest those upbeat assumptions and the related concerns about rising compliance costs in key markets may both need a fresh look.

Explore 2 other fair value estimates on Revvity - why the stock might be worth just $113.64!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Revvity research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Revvity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revvity's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.